Going against the current, Sorrento spins out pain-focused subsidiary in $140M SPAC deal

Amber Tong

Senior Editor

When Sorrento first unveiled plans to take its subsidiary Scilex public by merging with the blank check company Vickers Vantage Corp I last December, it was clinging to the tail-end of a fading SPAC boom in healthcare. In the few months since, the market has only chilled, with multiple deals getting axed and those that vaulted to Nasdaq earlier now struggling amid a broader biotech downturn.

None of that, though, is stopping Sorrento.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Going against the current, Sorrento spins out pain-focused subsidiary in $140M SPAC deal

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Katalin Karikó, Drew Weissman win Nobel Prize for mRNA discoveries

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA unveils new rare disease pilot program to increase agency-sponsor communications

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

CMIC: Japan’s first and largest CRO continues 30-year evolution to help global sponsors navigate the complex local ...

Go­ing against the cur­rent, Sor­ren­to spins out pain-fo­cused sub­sidiary in $140M SPAC deal

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Katal­in Karikó, Drew Weiss­man win No­bel Prize for mR­NA dis­cov­er­ies

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

CMIC: Japan’s first and largest CRO con­tin­ues 30-year evo­lu­tion to help glob­al spon­sors nav­i­gate the com­plex lo­cal ...

Going against the current, Sorrento spins out pain-focused subsidiary in $140M SPAC deal

Katalin Karikó, Drew Weissman win Nobel Prize for mRNA discoveries

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA unveils new rare disease pilot program to increase agency-sponsor communications

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

CMIC: Japan’s first and largest CRO continues 30-year evolution to help global sponsors navigate the complex local ...